SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.

Chamber Passed·6/9/26
Introduced Text

Pennsylvania SB866 amends the Controlled Substance, Drug, Device and Cosmetic Act to classify medetomidine as a Schedule III controlled substance and.

Pennsylvania SB866 amends the Controlled Substance, Drug, Device and Cosmetic Act to classify medetomidine as a Schedule III controlled substance. This bill also requires veterinarians to comply with specific storage and protection provisions for medetomidine and xylazine. The changes aim to regulate the use and distribution of medetomidine while ensuring its secure storage by authorized practitioners.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Last
Passed the Senate · 47–2 · Jun 9
Current
Judiciary Committee
Next
House floor vote

Sponsors

DD
2
2
RR
Democratic CaucusRepublican Caucus

Roll Call Votes

47 Yea

DDRDRDRRRRRRRRRRDRDRDRRDDRRDRDRDDRDDRDRRRDDRDDR

2 Nay

DD

1 Not Voting

D

Calendar

Jun 8

12:00 AM

Appropriations (s) Hearing

Jun 2

12:30 PM

Agriculture & Rural Affairs (s) Hearing

History

Jun 10

House

Referred to Judiciary

Jun 9

Senate

Third consideration and final passage (47-2)

Jun 9

House

In the House